FOR IMMEDIATE RELEASE

AMNEAL RECEIVES FDA APPROVAL FOR DEMECLOCYCLINE HCl TABLETS, USP

Paterson, New Jersey (USA), March 31, 2008 – Amneal Pharmaceuticals is pleased to announce that it received US FDA approval to manufacture Demeclocycline HCl Tablets, USP in strengths of 150mg and 300mg, effective February 27, 2008. Demeclocycline HCl is an AB-Rated, therapeutically equivalent alternative to Declomycin® (a trademark of Stonebridge Pharma).

The Demeclocycline approval is Amneal's 15th ANDA approval and continues to build the momentum for the aggressive growth Amneal is experiencing. Separately, in December, Amneal closed on the acquisition of a liquid Rx manufacturing plant in New Jersey and is currently negotiating to acquire several approved ANDAs.

Demeclocycline HCl is indicated in the treatment of infections caused by susceptible strains of the designated microorganisms in a number of conditions including Rocky Mountain spotted fever and respiratory tract infections. Amneal will begin shipping Demeclocycine HCl in the 150 and 300mg strengths as of March 17, 2008 and will have the product available through wholesalers-distributors as well as directly to the trade.

Amneal Pharmaceuticals LLC, headquartered in Paterson, NJ, is a USA-based firm that develops, manufacturers and distributes generic pharmaceutical products regulated and approved by the US FDA. Positioned as "Generic's New Generation," the company utilizes diverse R&D and manufacturing expertise to conceive breakthrough developments with lasting impact. Vigorous ANDA growth and broad product acquisitions are key features of Amneal's strategic growth plan, as is the company's commitment to building deep relationships with its customer base. Amneal delivers superior service levels, quality products, and dynamic value throughout the pharmaceutical industry.

###

CONTACT: Jim Luce, Executive Vice President-Sales & Marketing
Amneal Pharmaceuticals, LLC
Direct: 949-610-8018
Mobile: 949-633-2293
Fax: 949-610-8218
E-mail: jim@amneal.com
www.amneal.com
Corporate Headquarters
209 McLean Boulevard
Paterson, New Jersey 07504 USA